Alzheimer's Disease


Book Description

Nearly 44 million people have Alzheimer's or related dementia worldwide, according to the Alzheimer's Disease International organization. That number is expected to double every 20 years. Unlike other books on the market, Alzheimer's Disease: Understanding Biomarkers, Big Data, and Therapy covers recent advancements in cognitive, clinical, neural, and therapeutic aspects of Alzheimer's and other forms of dementia.First, readers are introduced to cognitive and clinical studies, focusing on the different types of memory impairment, past and future thinking. This includes the prevalence of depression, its relationship to other symptoms, and the quality of life for those with Alzheimer's disease. In addition, the book discusses recent studies on memory dysfunction in advanced-stage Alzheimer's disease, in comparison to early-stage, including a chapter on the underlying factors in the transition from mild cognitive impairment to Alzheimer's diagnosis. Following this section, the book presents recent studies on the role of different cortical and subcortical structures in the development of various symptoms in Alzheimer's disease, as well as different neural biomarkers underlying the development and treatment of the disease. In the last section of the book, therapeutic aspects of Alzheimer's disease, focusing on behavioral and pharmacological treatments of sleep disorders, memory problems, and depression, are reviewed. The book aids readers in understanding the advances in research and care, making it a prime tool for all clinicians, psychologists, researchers, neurologists, and caregivers of dementia patients. - Reviews recent developments of cognitive and clinical studies - Covers factors underlying the transition from mild cognitive impairment to Alzheimer's disease - Discusses different neural biomarkers underlying the development and treatment of Alzheimer's disease - Provides a comparison of the effectiveness of various types of treatments




The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia


Book Description

The guideline offers clear, concise, and actionable recommendation statements to help clinicians to incorporate recommendations into clinical practice, with the goal of improving quality of care. Each recommendation is given a rating that reflects the level of confidence that potential benefits of an intervention outweigh potential harms.




Neurology in Clinical Practice


Book Description

New edition, completely rewritten, with new chapters on endovascular surgery and mitochrondrial and ion channel disorders.




The Problem of Alzheimer's


Book Description

A definitive and compelling book on one of today's most prevalent illnesses. In 2020, an estimated 5.8 million Americans had Alzheimer’s, and more than half a million died because of the disease and its devastating complications. 16 million caregivers are responsible for paying as much as half of the $226 billion annual costs of their care. As more people live beyond their seventies and eighties, the number of patients will rise to an estimated 13.8 million by 2050. Part case studies, part meditation on the past, present and future of the disease, The Problem of Alzheimer's traces Alzheimer’s from its beginnings to its recognition as a crisis. While it is an unambiguous account of decades of missed opportunities and our health care systems’ failures to take action, it tells the story of the biomedical breakthroughs that may allow Alzheimer’s to finally be prevented and treated by medicine and also presents an argument for how we can live with dementia: the ways patients can reclaim their autonomy and redefine their sense of self, how families can support their loved ones, and the innovative reforms we can make as a society that would give caregivers and patients better quality of life. Rich in science, history, and characters, The Problem of Alzheimer's takes us inside laboratories, patients' homes, caregivers’ support groups, progressive care communities, and Jason Karlawish's own practice at the Penn Memory Center.




Alzheimer's Disease Theranostics


Book Description

Alzheimer's Disease Theranostics discusses the latest information on recent theranostic avenues for both the diagnosis and treatment of Alzheimer's patients. It presents the pros and cons of the probable mechanistic role of nanoparticles in crossing the blood-brain barrier and improving disease symptoms. Finally, it highlights the merits of existing maneuvers and suggests perspectives to aid in future developments. Despite the difficulty of drug delivery to the brain, there are some nanoparticulate platforms demonstrating promise in treating neurodegenerative disorders such as Alzheimer's disease. Manifold theranostic maneuvers include antioxidants, natural bioactive compounds, gene therapy, and nanotechnological approaches, all of which are discussed in this important work. - Examines various theranostic applications for the diagnosis and treatment of Alzheimer's disease - Features a comprehensive overview of nanoparticle therapeutics in the area and use of antioxidants - Assesses the common challenges and lessons learned from blood-brain barrier challenges, viral vector approaches and mitochondria-targeted therapeutics




Emerging Technologies for Diagnosing Alzheimer's Disease


Book Description

This book explores international biomedical research and development on the early diagnosis of Alzheimer's disease. It offers timely, multidisciplinary reflections on the social and ethical issues raised by promises of early diagnostics and asks under which conditions emerging diagnostic technologies can be considered a responsible innovation. The initial chapters in this edited volume provide an overview and a critical discussion of recent developments in biomedical research on Alzheimer's disease. Subsequent contributions explore the values at stake in current practices of dealing with Alzheimer's disease and dementia, both within and outside the biomedical domain. Novel diagnostic technologies for Alzheimer's disease emerge in a complex and shifting field, full of controversies. Innovating with care requires a precise mapping of how concepts, values and responsibilities are filled in through the confrontation of practices. In doing so, the volume offers a practice-based approach of responsible innovation that is also applicable to other fields of innovation.




The Alzheimer's Disease Challenge


Book Description

Alzheimer’s disease is undoubtedly the major health challenge of our Century with significant social and economic consequences. This Frontiers eBook offers a contribution of 39 innovative papers on the multidimensional and crucial problem of Alzheimer’s disease management and treatment. Several perspectives, research updates, and trials describing methods on potential diagnosis and treatment are presented including biological mechanisms, biomarkers and risk factors for an early and efficient prognosis, diagnosis and prevention. Additionally, while the rapidly increasing Alzheimer’s disease population demands holistic solutions and clinical studies with new therapeutic target approaches, several of the contributive papers present promising drugs targeting Alzheimer’s disease treatment. We give our deepest acknowledgment to all the authors for their important and innovative contributions, to the reviewers for their valuable recommendations on improving the submitting studies and all the Frontiers Editorial team for continuous support.




Biomarkers in Alzheimer's Disease


Book Description

Biomarkers in Alzheimer's Disease provides a comprehensive overview of all modalities of Alzheimer's disease biomarkers, including neuroimaging, cerebrospinal fluid, genomic, and peripheral systems. Each chapter integrates molecular/cellular abnormality due to Alzheimer's disease and technological advancement of biomarkers techniques. The book is ideal for clinical neuroscience and molecular/cellular neuroscience researchers, psychiatrists, and allied healthcare practitioners involved in the diagnosis and management of patients with cognitive impairment and Alzheimer's disease, and for differential diagnosis of Alzheimer's disease with other non-Alzheimer's dementia. - Presents a comprehensive overview detailing all modalities of Alzheimer's disease biomarkers - Written for neuroscience researchers and clinicians studying or treating patients with Alzheimer's Disease - Integrates, in each chapter, the molecular/cellular abnormality due to Alzheimer's disease and the technological advancement of biomarkers techniques




Alzheimer's Disease Drug Development


Book Description

Provides a definitive overview of the complex ecosystem facilitating Alzheimer's Disease drug research and development. Demonstrates a drug's journey from in the lab, clinical trial testing, regulatory review, and marketing by pharmaceutical companies. Details the use of artificial intelligence, clinical trial management, and financing models.




Reducing the Impact of Dementia in America


Book Description

As the largest generation in U.S. history - the population born in the two decades immediately following World War II - enters the age of risk for cognitive impairment, growing numbers of people will experience dementia (including Alzheimer's disease and related dementias). By one estimate, nearly 14 million people in the United States will be living with dementia by 2060. Like other hardships, the experience of living with dementia can bring unexpected moments of intimacy, growth, and compassion, but these diseases also affect people's capacity to work and carry out other activities and alter their relationships with loved ones, friends, and coworkers. Those who live with and care for individuals experiencing these diseases face challenges that include physical and emotional stress, difficult changes and losses in their relationships with life partners, loss of income, and interrupted connections to other activities and friends. From a societal perspective, these diseases place substantial demands on communities and on the institutions and government entities that support people living with dementia and their families, including the health care system, the providers of direct care, and others. Nevertheless, research in the social and behavioral sciences points to possibilities for preventing or slowing the development of dementia and for substantially reducing its social and economic impacts. At the request of the National Institute on Aging of the U.S. Department of Health and Human Services, Reducing the Impact of Dementia in America assesses the contributions of research in the social and behavioral sciences and identifies a research agenda for the coming decade. This report offers a blueprint for the next decade of behavioral and social science research to reduce the negative impact of dementia for America's diverse population. Reducing the Impact of Dementia in America calls for research that addresses the causes and solutions for disparities in both developing dementia and receiving adequate treatment and support. It calls for research that sets goals meaningful not just for scientists but for people living with dementia and those who support them as well. By 2030, an estimated 8.5 million Americans will have Alzheimer's disease and many more will have other forms of dementia. Through identifying priorities social and behavioral science research and recommending ways in which they can be pursued in a coordinated fashion, Reducing the Impact of Dementia in America will help produce research that improves the lives of all those affected by dementia.